Literature DB >> 17697443

Trends in resistance to penicillin and erythromycin of invasive pneumococci in Portugal.

R Dias1, M Caniça.   

Abstract

Antimicrobial resistance of pneumococci is influenced by serotypes, antimicrobial consumption and vaccine use. Serotyping of 697 out of 1331 pneumococcal isolates, recovered in Portugal from 1994 to 2004, showed that the theoretical rate of heptavalent conjugate vaccine coverage was 91.7% and 63.6% for penicillin and erythromycin non-susceptible strains, respectively, in children up to 1 year old. The use of amoxicillin and erythromycin decreased in the vaccine period 2001-2004 (P=0.04 and P<0.01, respectively) but azithromycin usage increased in the same period (P<0.01). By using linear regression models, we evaluated the role of antimicrobial and vaccine use in the trends of resistance to penicillin and erythromycin among the isolates. The models suggest that the use of macrolides was the main factor associated with an increase of penicillin and erythromycin non-susceptible isolates from adults (P<0.01) and erythromycin non-susceptible isolates among children (P=0.006). These models also suggest that heptavalent vaccine is failing to reduce antimicrobial resistance as expected, possibly due to the increased consumption of azithromycin (P=0.04). The efficient use of new antibiotics may reverse the present trends of antimicrobial resistance.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17697443      PMCID: PMC2870878          DOI: 10.1017/S0950268807009405

Source DB:  PubMed          Journal:  Epidemiol Infect        ISSN: 0950-2688            Impact factor:   2.451


  33 in total

1.  In vitro activity of extended-spectrum cephalosporins against Streptococcus pneumoniae strains with reduced susceptibility to penicillin isolated from patients in Portugal between 1995 and 2000.

Authors:  Manuela Caniça; Ricardo Dias; Deolinda Louro; Catarina Carvalho
Journal:  J Antimicrob Chemother       Date:  2002-10       Impact factor: 5.790

2.  Effect of a conjugate pneumococcal vaccine on the occurrence of respiratory infections and antibiotic use in day-care center attendees.

Authors:  R Dagan; M Sikuler-Cohen; O Zamir; J Janco; N Givon-Lavi; D Fraser
Journal:  Pediatr Infect Dis J       Date:  2001-10       Impact factor: 2.129

3.  Antimicrobial susceptibility of invasive Streptococcus pneumoniae isolates in Portugal over an 11-year period.

Authors:  Ricardo Dias; Deolinda Louro; Manuela Caniça
Journal:  Antimicrob Agents Chemother       Date:  2006-06       Impact factor: 5.191

4.  Influence of macrolide antibiotics on promotion of resistance in the oral flora of children.

Authors:  U Kastner; J P Guggenbichler
Journal:  Infection       Date:  2001-10       Impact factor: 3.553

Review 5.  Surveillance of resistance in bacteria causing community-acquired respiratory tract infections.

Authors:  David Felmingham; C Feldman; W Hryniewicz; K Klugman; S Kohno; D E Low; C Mendes; A C Rodloff
Journal:  Clin Microbiol Infect       Date:  2002       Impact factor: 8.067

6.  Effects of amoxicillin/clavulanate or azithromycin on nasopharyngeal carriage of Streptococcus pneumoniae and Haemophilus influenzae in children with acute otitis media.

Authors:  F Ghaffar; L S Muniz; K Katz; J Reynolds; J L Smith; P Davis; I R Friedland; G H McCracken
Journal:  Clin Infect Dis       Date:  2000-10-25       Impact factor: 9.079

Review 7.  The problem with cephalosporins.

Authors:  S J Dancer
Journal:  J Antimicrob Chemother       Date:  2001-10       Impact factor: 5.790

8.  A European study on the relationship between antimicrobial use and antimicrobial resistance.

Authors:  Stef L A M Bronzwaer; Otto Cars; Udo Buchholz; Sigvard Mölstad; Wim Goettsch; Irene K Veldhuijzen; Jacob L Kool; Marc J W Sprenger; John E Degener
Journal:  Emerg Infect Dis       Date:  2002-03       Impact factor: 6.883

Review 9.  Antibiotic consumption and resistance selection in Streptococcus pneumoniae.

Authors:  F Baquero; G Baquero-Artigao; R Cantón; C García-Rey
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

Review 10.  The successful clone: the vector of dissemination of resistance in Streptococcus pneumoniae.

Authors:  K P Klugman
Journal:  J Antimicrob Chemother       Date:  2002-12       Impact factor: 5.790

View more
  6 in total

1.  Temporal trends of antimicrobial resistance and clonality of invasive Streptococcus pneumoniae isolates in Finland, 2002 to 2006.

Authors:  Lotta Siira; Merja Rantala; Jari Jalava; Antti J Hakanen; Pentti Huovinen; Tarja Kaijalainen; Outi Lyytikäinen; Anni Virolainen
Journal:  Antimicrob Agents Chemother       Date:  2009-03-09       Impact factor: 5.191

2.  Macrolide susceptibility and serotype specific macrolide resistance of invasive isolates of Streptococcus pneumoniae in Germany from 1992 to 2008.

Authors:  Matthias Imöhl; Ralf René Reinert; Christina Mutscher; Mark van der Linden
Journal:  BMC Microbiol       Date:  2010-11-25       Impact factor: 3.605

3.  Effects of long-term use of macrolides in patients with non-cystic fibrosis bronchiectasis: a meta-analysis of randomized controlled trials.

Authors:  Li-Chao Fan; Hai-Wen Lu; Ping Wei; Xiao-Bin Ji; Shuo Liang; Jin-Fu Xu
Journal:  BMC Infect Dis       Date:  2015-03-27       Impact factor: 3.090

4.  Emerging resistant serotypes of invasive Streptococcus pneumoniae.

Authors:  Sittana Elshafie; Saad J Taj-Aldeen
Journal:  Infect Drug Resist       Date:  2016-06-29       Impact factor: 4.003

5.  Effect on Antimicrobial Resistance of a Policy Restricting Over-the-Counter Antimicrobial Sales in a Large Metropolitan Area, São Paulo, Brazil.

Authors:  Maria L Moura; Icaro Boszczowski; Manuela Blaque; Rafael M Mussarelli; Victor Fossaluza; Ligia C Pierrotti; Gustavo Campana; Maria C Brandileone; Rosemeire Zanella; Samanta C G Almeida; Anna S Levin
Journal:  Emerg Infect Dis       Date:  2022-01       Impact factor: 6.883

Review 6.  Efficacy and safety of azithromycin in Covid-19 patients: A systematic review and meta-analysis of randomized clinical trials.

Authors:  Ahmed M Kamel; Mona S A Monem; Nour A Sharaf; Nada Magdy; Samar F Farid
Journal:  Rev Med Virol       Date:  2021-06-02       Impact factor: 11.043

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.